Published in Arch Neurol on July 10, 2006
Reversing cognitive-motor impairments in Parkinson's disease patients using a computational modelling approach to deep brain stimulation programming. Brain (2010) 1.62
Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain (2008) 1.51
Mechanisms and targets of deep brain stimulation in movement disorders. Neurotherapeutics (2008) 1.42
Differences among implanted pulse generator waveforms cause variations in the neural response to deep brain stimulation. Clin Neurophysiol (2007) 1.35
Current steering to control the volume of tissue activated during deep brain stimulation. Brain Stimul (2008) 1.13
A noninvasive imaging approach to understanding speech changes following deep brain stimulation in Parkinson's disease. Am J Speech Lang Pathol (2008) 1.09
Does suppression of oscillatory synchronisation mediate some of the therapeutic effects of DBS in patients with Parkinson's disease? Front Integr Neurosci (2012) 1.08
Current steering to activate targeted neural pathways during deep brain stimulation of the subthalamic region. Brain Stimul (2011) 1.00
Artificial neural network based characterization of the volume of tissue activated during deep brain stimulation. J Neural Eng (2013) 0.97
A neurochemical closed-loop controller for deep brain stimulation: toward individualized smart neuromodulation therapies. Front Neurosci (2014) 0.96
Deep brain stimulation in the nucleus ventralis intermedius in patients with essential tremor: habituation of tremor suppression. J Neurol (2010) 0.93
Engineering the next generation of clinical deep brain stimulation technology. Brain Stimul (2014) 0.92
Deep brain stimulation in Parkinson's disease. Ther Adv Neurol Disord (2009) 0.90
Double-blind optimization of subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study. J Psychiatry Neurosci (2013) 0.89
Recording evoked potentials during deep brain stimulation: development and validation of instrumentation to suppress the stimulus artefact. J Neural Eng (2012) 0.89
Retrospective review of factors leading to dissatisfaction with subthalamic nucleus deep brain stimulation during long-term management. Surg Neurol Int (2013) 0.86
Characterizing effects of subthalamic nucleus deep brain stimulation on methamphetamine-induced circling behavior in hemi-Parkinsonian rats. IEEE Trans Neural Syst Rehabil Eng (2012) 0.81
Neural origin of evoked potentials during thalamic deep brain stimulation. J Neurophysiol (2013) 0.80
Phase-dependent modulation as a novel approach for therapeutic brain stimulation. Front Comput Neurosci (2015) 0.79
Failure of long-term subthalamic nucleus stimulation corrected by additional pallidal stimulation in a patient with Parkinson's disease. J Neurol (2011) 0.77
Motion sensor strategies for automated optimization of deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord (2015) 0.77
Theoretical Optimization of Stimulation Strategies for a Directionally Segmented Deep Brain Stimulation Electrode Array. IEEE Trans Biomed Eng (2015) 0.76
Parkinson disease: deep brain stimulation in Parkinson disease-what went wrong? Nat Rev Neurol (2010) 0.76
Web-based telemonitoring and delivery of caregiver support for patients with Parkinson disease after deep brain stimulation: protocol. JMIR Res Protoc (2015) 0.76
Neurosurgery: Complications of DBS surgery - insights from large databases. Nat Rev Neurol (2016) 0.75
Pulsatile desynchronizing delayed feedback for closed-loop deep brain stimulation. PLoS One (2017) 0.75
Computer-Guided Deep Brain Stimulation Programming for Parkinson's Disease. Neuromodulation (2015) 0.75
Technology for deep brain stimulation at a gallop. Mov Disord (2015) 0.75
Rapid assessment of gait and speech after subthalamic deep brain stimulation. Surg Neurol Int (2016) 0.75
Advances in closed-loop deep brain stimulation devices. J Neuroeng Rehabil (2017) 0.75
Bilateral subthalamic stimulation for advanced Parkinson disease: early experience at an Eastern center. Neurol Sci (2014) 0.75
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain (2007) 4.13
Mechanisms of deep brain stimulation. Mov Disord (2002) 3.91
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet (2013) 3.21
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol (2010) 2.64
A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol (2010) 2.64
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol (2008) 2.46
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry (2011) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol (2013) 2.37
Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry (2010) 2.36
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron (2004) 2.29
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
The subthalamic nucleus in the context of movement disorders. Brain (2003) 2.10
Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain (2009) 2.05
Highly cited works in neurosurgery. Part II: the citation classics. J Neurosurg (2010) 2.04
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
The FM/AM world is shaping the future of deep brain stimulation. Mov Disord (2014) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. J Neurosurg (2009) 1.79
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci (2011) 1.79
Chronic anterior thalamus stimulation for intractable epilepsy. Epilepsia (2002) 1.78
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
The subcallosal cingulate gyrus in the context of major depression. Biol Psychiatry (2010) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Highly cited works in neurosurgery. Part I: the 100 top-cited papers in neurosurgical journals. J Neurosurg (2010) 1.64
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Direct visualization of deep brain stimulation targets in Parkinson disease with the use of 7-tesla magnetic resonance imaging. J Neurosurg (2010) 1.57
Deep brain stimulation: postoperative issues. Mov Disord (2006) 1.57
Human anterior cingulate cortex neurons encode cognitive and emotional demands. J Neurosci (2005) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54